Traders Purchase High Volume of Recursion Pharmaceuticals Call Options (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was the recipient of some unusual options trading activity on Wednesday. Investors bought 7,667 call options on the stock. This is an increase of 58% compared to the average daily volume of 4,843 call options.

Analyst Ratings Changes

A number of equities research analysts have weighed in on RXRX shares. Leerink Partners lowered their price target on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a research report on Tuesday, September 3rd. Needham & Company LLC restated a “buy” rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a research report on Wednesday. Finally, Jefferies Financial Group cut their target price on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research note on Tuesday, September 3rd. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $9.25.

Recursion Pharmaceuticals Trading Down 4.1 %

NASDAQ RXRX opened at $5.79 on Friday. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals has a 1-year low of $5.62 and a 1-year high of $15.74. The stock has a 50-day moving average of $6.63 and a 200-day moving average of $7.53. The firm has a market cap of $1.66 billion, a PE ratio of -3.79 and a beta of 0.81.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). The firm had revenue of $26.08 million during the quarter, compared to the consensus estimate of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. Recursion Pharmaceuticals’s revenue was up 147.6% on a year-over-year basis. During the same period last year, the business earned ($0.43) EPS. As a group, sell-side analysts forecast that Recursion Pharmaceuticals will post -1.56 EPS for the current year.

Insider Buying and Selling at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, CEO Christopher Gibson sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $6.04, for a total value of $120,800.00. Following the completion of the transaction, the chief executive officer now owns 762,656 shares of the company’s stock, valued at $4,606,442.24. The trade was a 2.56 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Tina Marriott sold 6,000 shares of the firm’s stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $7.56, for a total transaction of $45,360.00. Following the sale, the chief operating officer now owns 521,138 shares in the company, valued at approximately $3,939,803.28. This trade represents a 1.14 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 171,682 shares of company stock valued at $1,133,471 in the last three months. Company insiders own 15.75% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Perceptive Advisors LLC bought a new stake in shares of Recursion Pharmaceuticals in the 2nd quarter worth approximately $5,769,000. Pier 88 Investment Partners LLC increased its position in Recursion Pharmaceuticals by 442.1% during the 3rd quarter. Pier 88 Investment Partners LLC now owns 133,910 shares of the company’s stock valued at $882,000 after purchasing an additional 109,210 shares during the period. Benjamin F. Edwards & Company Inc. raised its holdings in Recursion Pharmaceuticals by 6,439.6% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 169,900 shares of the company’s stock worth $1,274,000 after purchasing an additional 167,302 shares in the last quarter. Scientech Research LLC purchased a new stake in shares of Recursion Pharmaceuticals in the 2nd quarter worth about $1,052,000. Finally, Ghisallo Capital Management LLC bought a new stake in shares of Recursion Pharmaceuticals during the 2nd quarter valued at about $8,250,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.